Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

European Partners Combine to Bring Therapeutic Antibody to Market

By BiotechDaily International staff writers
Posted on 15 Aug 2013
Two European biotechnology companies have agreed to collaborate to complete development and commence marketing of a novel therapeutic antibody that targets the GD2 antigen, which is abundantly expressed on neuroblastoma cells.

Neuroblastoma is a cancer of the sympathetic nervous system that accounts for about 7% of all childhood cancers and 10% to 15% of all childhood cancer deaths.

Apeiron Biologics AG (Vienna, Austria), a biotech company focused on immunologic and biologic therapies against cancer, has agreed to a joint project with Rentschler Biotechnologie GmbH (Laupheim, Germany), a full service biopharmaceutical contract manufacturer, to complete development of the chimeric APN311 antibody for advanced clinical studies and then to manufacture it under full GMP compliance.

Per the agreement, Apeiron will receive access to experienced teams, appropriate mammalian cell culture capacity for clinical phase I to III trials, commercial production, fill and finish services as well as a scientifically driven, and responsive project management. The manufacturing process, validation, and regulatory affairs will be transferred to Rentschler.

Hans Loibner, CEO of Apeiron Biologics, said, "We are happy to have identified Rentschler as a professional contract manufacturer and consider this collaboration as a distinct value increase for our project APN311, which is also acknowledged in discussions with existing and potential partners. This decision resolved a significant hurdle in our effort to make this therapy available as soon as possible. I am very much looking forward to a fruitful collaboration."

"We are very excited to contribute our expertise to meet the truly challenging timeline of this project which is so very important for children suffering from this life threatening disease," said Frank Ternes, chief business officer at Rentschler. "We are confident that this cooperative atmosphere will continue to grow and mature over the course of the entire project, and ensure the success of this partnership."

Related Links:
Apeiron Biologics AG
Rentschler Biotechnologie GmbH



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Drug Discovery

view channel
Image: The five stages of biofilm development: (1) Initial attachment, (2) Irreversible attachment, (3) Maturation I, (4) Maturation II, and (5) Dispersion. Each stage of development in the diagram is paired with a photomicrograph of a developing P. aeruginosa biofilm. All photomicrographs are shown to same scale (Photo courtesy of Wikimedia Commons).

Ionic Liquids Disperse Bacterial Biofilms and Increase Antibiotic Susceptibility

The ionic liquid choline-geranate was shown to effectively eliminate the protective biofilm generated by bacteria such as Salmonella enterica and Pseudomonas aeruginosa and to significantly increase the... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.